Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

1. An oral unit dosage form comprising:

an active pharmaceutical ingredient (API) consisting essentially of a Type A solid form of (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile, wherein the solid form is characterized by a differential scanning calorimetry (DSC) thermogram with an endothermic event at about 256.6° C., and

one or more excipients selected from the group consisting of a filler, a disintegrant, a lubricant, and a glidant.

2. The oral unit dosage form of claim 1 , wherein the oral unit dosage form comprises one or more of: (a) about 5 wt % croscarmellose sodium, (b) about 60 wt % microcrystalline cellulose, and (c) about 1 wt % magnesium stearate.

3. An oral unit dosage form comprising:

(a) a Type A solid form of (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; and

(b) one or more components selected from the group consisting of microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

4. An oral unit dosage form comprising 50-150 mg of a solid form of Compound 1:

characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 6.3, 12.8, 13.8, 23.6, and 27.8, and one or more excipients.

5. The oral unit dosage form of claim 4 , wherein the excipients comprise a filler, a disintegrant, and a lubricant; and wherein the solid form of Compound 1 is characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 6.3, 12.8, 13.8, 23.6, and 27.8, corresponding to d-spacing (angstroms±0.2) of 14.0, 6.9, 6.4, 3.8, and 3.2, respectively.

6. The oral unit dosage form of claim 5 , wherein the solid form of Compound 1 is characterized by an X-ray Powder Diffraction (XRPD) having diffractions at angles (2 theta±0.2) of 5.7, 6.3, 8.5, 10.6, 12.8, 13.8, 17.3, 22.0, 22.8, 23.6, and 27.8.

7. The oral unit dosage form of claim 4 , wherein the solid form of Compound 1 is characterized by an X-ray Powder Diffraction (XRPD) having further diffractions at angles (2 theta±0.2) of 5.7, 8.5, 10.6, 17.3, 22.0, and 22.8 corresponding to d-spacing (angstroms±0.2) of 15.4, 10.4, 8.4, 5.1, 4.0, and 3.9, respectively.

8. The oral unit dosage form of claim 7 , wherein the solid form of Compound 1 is characterized by an X-ray Powder Diffraction (XRPD) having peaks at the angles (2θ±0.21 and corresponding d-spacing (ű0.2) of:

d-spacing

2θ ± 0.2

Å ± 0.2

5.7

15.4

6.3

14.0

8.5

10.4

10.6

8.4

11.4

7.8

12.8

6.9

13.8

6.4

14.2

6.2

15.2

5.8

15.6

5.7

17.3

5.1

17.9

5.0

18.2

4.9

18.9

4.7

19.6

4.5

20.6

4.3

21.5

4.1

22.0

4.0

22.8

3.9

23.6

3.8

24.5

3.6

24.8

3.6

25.3

3.5

25.6

3.5

26.0

3.4

26.3

3.4

27.0

3.3

27.8

3.2

28.9

3.1

30.0

3.0

31.2

3.0

32.1

2.8

33.6

2.7

34.1

2.6

36.3

2.5

37.0

2.4

38.1

2.4

9. The oral unit dosage form of claim 4 , wherein the solid form of Compound 1 is characterized by a differential scanning calorimetry (DSC) thermogram with an endothermic event at about 256.6° C.

10. The oral unit dosage form of claim 4 , wherein the solid form of Compound 1 is characterized by a dynamic vapor sorption (DVS) showing maximum water uptake of 0.25% w/w at 25° C./90% RH.

11. The oral unit dosage form of claim 4 , wherein the oral unit dosage form is a capsule comprising a total of 50 mg of Compound 1.

12. The oral unit dosage form of claim 4 , wherein the oral unit dosage form is a capsule comprising a total of 150 mg of Compound 1.

13. The oral unit dosage form of claim 4 , wherein the one or more excipients comprise microcrystalline cellulose, croscarmellose sodium, and magnesium stearate in a weight ratio of about 61:5:1.

14. The oral unit dosage form of claim 4 , wherein the oral unit dosage form is a capsule comprising Compound 1 and the excipients in a weight ratio of about 33:67.

15. The oral unit dosage form of claim 4 , wherein the oral unit dosage form is a capsule having the composition described in Table 4-1:

Table 4-1

TABLE 4-1

Dose

Relative

Strength

Component

weight

50 mg or

Compound 1 Type A, Micronized

33.00

150 mg

Microcrystalline Cellulose NF/EP

61.12

(Avicel PH101)

Croscarmellose Sodium NF/EP

4.95

Magnesium Stearate NF/EP

1.00

Hard gelatin capsule shell, size 2 or

wt x

size 00, white opaque

16. The oral unit dosage form of claim 1 , wherein the one or more excipients comprise one or more of: (a) microcrystalline cellulose; (b) croscarmellose sodium; and (c) magnesium stearate.

17. The oral unit dosage form of claim 16 , wherein the composition comprises the olutasidenib and the filler in a weight ratio of about 1:2.

18. The oral unit dosage form of claim 17 , wherein the composition comprises the olutasidenib and the filler in a weight ratio of about 33:61.

19. The oral unit dosage form of claim 1 , comprising about 30-35% by weight of olutasidenib.

20. A unit dosage form comprising olutasidenib in a Type A solid form, and one or more excipients.

21. The unit dosage form of claim 20 , wherein the unit dosage form comprises 50-150 mg olutasidenib.

22. The unit dosage form of claim 21 , wherein the unit dosage form comprises 50 mg olutasidenib.

23. The unit dosage form of claim 22 , wherein the unit dosage form is a tablet.

24. The unit dosage form of claim 22 , wherein the unit dosage form is a capsule.

25. The unit dosage form of claim 21 , wherein the unit dosage form comprises 150 mg olutasidenib.

26. The unit dosage form of claim 25 , wherein the unit dosage form is a tablet.

27. The unit dosage form of claim 25 , wherein the unit dosage form is a capsule.

28. The unit dosage form of claim 20 , wherein the one or more excipients are selected from the group consisting of a filler, a disintegrant, a lubricant, and a glidant.

29. The unit dosage form of claim 20 , wherein the one or more excipients are selected from the group consisting of (a) microcrystalline cellulose; (b) croscarmellose sodium; and (c) magnesium stearate.

30. The unit dosage form of claim 20 , comprising micronized olutasidenib.

31. The unit dosage form of claim 30 , wherein the unit dosage form is a tablet comprising 150 mg olutasidenib.

32. The unit dosage form of claim 31 , wherein about 33% w/w of the tablet is olutasidenib.